Q3 Revenue Up 9% but Adjusted EBITDA Falls 8% as Artivion Narrows Guidance
AORT sits 32% above its 52-week low of $19.16 on elevated volume (1.8× avg).
Summary
Revenue rose 9% to $123.8 million, beating analyst expectations on On-X growth, but the quality of the quarter was weak: GAAP swung to a $(7.9) million net loss, or $(0.16) per share, from $6.5 million of income a year ago, and adjusted EBITDA fell 8% to $22.5 million. Non-GAAP net income of $3.8 million ($0.08 per share) was half last year's $7.9 million. Management narrowed full-year 2026 revenue guidance to $484-492 million (8-10% constant-currency growth) from $480-496 million, and adjusted EBITDA to $93-98 million from $92-99 million. The bull case rests on the AMDS and NEXUS PMAs and the January 2027 NEXUS U.S. launch, with a first surgeon training event in December; the near-term problem is margin pressure from Endospan integration costs and a $363.8 million debt load against $48.4 million of cash.
At the time of this announcement, AORT was trading at $25.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $19.16 to $48.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.